Breaking News Instant updates and real-time market news.

VRAY

ViewRay

$2.69

0.115 (4.47%)

10:35
10/15/19
10/15
10:35
10/15/19
10:35

ViewRay preannounced better than expected Q3, says Piper Jaffray

ViewRay this morning preannounced better than expected Q3 sales results after installing three systems compared to the Street estimate at two, Piper Jaffray analyst Matt O'Brien tells investors in a research note. Further, the eight MRIdian system orders in Q3, including three upgrades, were in-line with expectations and a "welcome sight" as investors had worried that hesitancy around the proposed reimbursement bundle would result in significant delays in purchasing decisions, adds the analyst. He views the results as "largely positive" and reiterates an Overweight rating on ViewRay shares with a $6 price target. O'Brien, who admits the company's cash burn was a little higher than he had modeled, sees a "compelling entry point" at current ViewRay share levels.

  • 12

    Nov

VRAY ViewRay
$2.69

0.115 (4.47%)

08/09/19
JEFF
08/09/19
NO CHANGE
Target $7
JEFF
Buy
ViewRay price target lowered to $7 from $14 at Jefferies
Jefferies analyst Anthony Petrone halved his price target for ViewRay to $7 from $14 saying "all that could go wrong went wrong" in Q2. The company's orders fell short, sales guidance was slashed $30M at the midpoint on slower installs, driving cash burn $15M higher at the midpoint, and it announced the resignation of its CFO in the coming weeks, Petrone tells investors in a research note. The analyst, however, remains positive on the long-term prospects for MRIdian. He keeps a Buy rating on ViewRay.
08/19/19
PIPR
08/19/19
NO CHANGE
PIPR
Overweight
ViewRay prostate cancer study findings 'highly compelling,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien said he views the results of ViewRay's prostate cancer study as "a highly compelling example of the unique advantages of the MRIdian system" and thinks these results, along with further MRIdian data, should continue to make the selling process for the company easier. The analyst, who expects ViewRay to take market share in upcoming quarters, keeps an Overweight rating on the stock.
09/13/19
CANT
09/13/19
NO CHANGE
Target $6
CANT
Overweight
Cantor sees upcoming radiation meeting as positive for ViewRay
Cantor Fitzgerald analyst Craig Bijou expects the American Society for Radiation Oncology annual meeting, being held September 15-19 in Chicago, to be positive for ViewRay. He believes conference buzz will be centered on the radiation oncology alternative payment model, the overall competitive environment, and clinical data. ViewRay will have an opportunity to raise its exposure to the industry, says Bijou, who reiterates an Overweight rating on the shares with a $6 price target.
09/16/19
PIPR
09/16/19
NO CHANGE
Target $6
PIPR
Overweight
ViewRay recent orders 'incremental positives,' says Piper Jaffray
ViewRay this morning announced that Penn State Health has entered a master agreement to purchase up to four MRIdian systems with the immediate order of one system and the ability to order an additional three systems in the future, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This news follows an announcement last Thursday of an MRIdian order from Stanford Health Care, adds the analyst. He views these orders as "incremental positives" and further evidence of the "unique capabilities" of the MRIdian system. O'Brien reiterates an Overweight rating on ViewRay with a $6 price target.

TODAY'S FREE FLY STORIES

ADSK

Autodesk

$165.15

-0.19 (-0.11%)

07:47
11/22/19
11/22
07:47
11/22/19
07:47
Recommendations
Autodesk analyst commentary  »

Autodesk should meet or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 02

    Dec

LOW

Lowe's

$116.96

-0.88 (-0.75%)

, HD

Home Depot

$218.56

-2.28 (-1.03%)

07:43
11/22/19
11/22
07:43
11/22/19
07:43
Recommendations
Lowe's, Home Depot analyst commentary  »

Lowe's price target…

LOW

Lowe's

$116.96

-0.88 (-0.75%)

HD

Home Depot

$218.56

-2.28 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 11

    Dec

  • 25

    Feb

PZZA

Papa John's

$61.47

1.2 (1.99%)

07:42
11/22/19
11/22
07:42
11/22/19
07:42
Recommendations
Papa John's analyst commentary  »

Papa John's checks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TSLA

Tesla

$354.82

2.49 (0.71%)

07:41
11/22/19
11/22
07:41
11/22/19
07:41
Recommendations
Tesla analyst commentary  »

Tesla pickup unveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRMK

Broadmark Realty Capital

$10.94

-0.02 (-0.18%)

07:40
11/22/19
11/22
07:40
11/22/19
07:40
Initiation
Broadmark Realty Capital initiated  »

Broadmark Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
11/22/19
11/22
07:40
11/22/19
07:40
General news
Treasury Market Outlook: bond yields are modestly richer outside of Asia »

Treasury Market Outlook:…

NKSH

National Bankshares

$47.08

1.59 (3.50%)

07:39
11/22/19
11/22
07:39
11/22/19
07:39
Downgrade
National Bankshares rating change  »

National Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$2.03

0.01 (0.50%)

07:37
11/22/19
11/22
07:37
11/22/19
07:37
Initiation
Precipio initiated  »

Precipio initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$288.66

3.68 (1.29%)

07:36
11/22/19
11/22
07:36
11/22/19
07:36
Hot Stocks
Biogen announces results from Phase 3 EVOLVE-MS-2 study »

Biogen announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

APDN

Applied DNA Sciences

$4.14

(0.00%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Upgrade
Applied DNA Sciences rating change  »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$126.80

-0.04 (-0.03%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

LYFT

Lyft

$46.77

2.92 (6.66%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

ZM

Zoom Video

$69.91

-1.02 (-1.44%)

07:34
11/22/19
11/22
07:34
11/22/19
07:34
Initiation
Zoom Video initiated  »

Guggenheim starts Zoom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:33
11/22/19
11/22
07:33
11/22/19
07:33
Hot Stocks
Auxly says company 'ready to enter' Cannabis 2.0 market on first day of sales »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

, F

Ford

$8.72

-0.005 (-0.06%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Recommendations
Tesla, Ford, General Motors analyst commentary  »

Tesla's $39,900…

TSLA

Tesla

F

Ford

$8.72

-0.005 (-0.06%)

GM

General Motors

$34.66

-0.6 (-1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 09

    Dec

  • 04

    Feb

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMSY

HMS Holdings

$29.51

0.52 (1.79%)

07:32
11/22/19
11/22
07:32
11/22/19
07:32
Upgrade
HMS Holdings rating change  »

Guggenheim upgrades HMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:31
11/22/19
11/22
07:31
11/22/19
07:31
Earnings
Auxly Cannabis reports Q3 EPS (C$0.03) vs. (C$0.02) last year »

Reports Q3 revenue C$1.6M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXE

Anixter

$85.30

-0.41 (-0.48%)

07:30
11/22/19
11/22
07:30
11/22/19
07:30
Hot Stocks
Anixter, CD&R announce amendment to up merger consideration to $82.50 per share »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$63.42

-0.09 (-0.14%)

07:28
11/22/19
11/22
07:28
11/22/19
07:28
Downgrade
Cognizant rating change  »

Cognizant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBS

Emergent BioSolutions

$52.46

-1.9 (-3.50%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Recommendations
Emergent BioSolutions analyst commentary  »

Cantor reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$47.17

1.2 (2.61%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Periodicals
Sanofi EVP in charge of strategy leaving by end of month, Reuters says »

Muzammil Mansuri,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

NXRT

NexPoint Residential

$47.61

-0.49 (-1.02%)

07:27
11/22/19
11/22
07:27
11/22/19
07:27
Initiation
NexPoint Residential initiated  »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$28.49

-0.15 (-0.52%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Initiation
Apellis initiated  »

Apellis has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

KKR

KKR

$29.07

-0.25 (-0.85%)

07:26
11/22/19
11/22
07:26
11/22/19
07:26
Periodicals
KKR gets halfway in $3B Asia infrastructure fundraising, Reuters says »

According to Reuters, KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.